1. Giudicessi J.R., Ackerman M.J. Calcium Revisited: New Insights Into the Molecular Basis of Long-QT Syndrome. Circ Arrhythm Electrophysiol. 2016; 9 (7): e002480. doi: 10.1161/CIRCEP.116.002480
2. Kim J.A., Chelu M.G. Inherited Arrhythmia Syndromes. Tex Heart Inst J. 2021; 48 (4): e207482. doi: 10.14503/THIJ-20-7482
3. Wallace E., Howard L., Liu M., O'Brien T., Ward D., Shen S., Prendiville T. Long QT Syndrome: Genetics and Future Perspective. Pediatr Cardiol. 2019; 40 (7): 1419-1430. doi: 10.1007/s00246-019-02151-x
4. Lopez K.N., Nunez-Gallegos F., Wang Y., Cannon B., Kim J., Valdes S. Long qt syndrome in the hispanic population: a comparative study. J Am Coll Cardiol. 2018; 71 (11_Supplement): A430.
5. Chen L., Sampson K.J., Kass R.S. Cardiac delayed rectifier potassium channels in health and disease. Cardiac Electrophysiol Clin. 2016; 8 (2): 307–322. doi: 10.1016/j.ccep.2016.01.004
6. Barsheshet A., Goldenberg I., O-Uchi J., Moss A.J., Jons C., Shimizu W., Wilde A.A., McNitt S., Peterson D.R., Zareba W., Robinson J.L., Ackerman M.J., Cypress M., Gray D.A., Hofman N., Kanters J.K., Kaufman E.S., Platonov P.G., Qi M., Towbin J.A., Vincent G.M., Lopes C.M. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to beta-blocker therapy in type 1 long-QT syndrome. Circulation. 2012; 125 (16): 1988–1996. doi: 10.1161/CIRCULATIONAHA.111.048041
7. Davis R.P., Casini S., van den Berg C.W., Hoekstra M., Remme C.A., Dambrot C., Salvatori D., Oostwaard D.W., Wilde A.A., Bezzina C.R., Verkerk A.O., Freund C., Mummery C.L. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation. 2012; 125 (25): 3079–3091. doi: 10.1161/CIRCULATIONAHA.111.066092
8. Abriel H. Cardiac sodium channel Na(v)1.5 and interacting proteins: physiology and pathophysiology. J Mol Cell Cardiol. 2010; 48 (1): 2–11. doi: 10.1016/j.yjmcc.2009.08.025
9. Mizusawa Y., Horie M., Wilde A.A. Genetic and clinical advances in congenital long QT syndrome. Circ J. 2014; 78 (12): 2827–2833
10. Peasey A., Bobak M., Kubinova R., Malyutina S., Pajak A., Tamosiunas A., Pikhart H., Nicholson A., Marmot M. Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: Rationale and design of the HAPIEE study. BMC Public Health. 2006; 6 (255). doi: 10.1186/1471-2458-6-255
11. Ragino Yu.I., Kuzminykh N.A., Shcherbakova L.V., Denisova D.V., Shramko V.S., Voevoda M.I. Prevalence of coronary heart disease (by epidemiological criteria) and its association with lipid and non-lipid risk factors in the Novosibirsk population of 25-45 years. Russian Journal of Cardiology. 2019; (6): 78-84. doi: 10.15829/1560-4071-2019-6-78-84.
12. Indraratna P., Tardo D., Delves M., Szirt R. , Ng B. Measurement and Management of QT Interval Prolongation for General Physicians. J Gen Intern Med. 2020; 35 (3): 865-873. doi: 10.1007/s11606-019-05477-7
13. Taran L.M., Szilagyi N. The duration of the electrical systole (QT) in acute rheumatic carditis in children. Am Heart J. 1947; 33: 14-26.
14. Sambrook J., Russell D.W. Purification of nucleic acids by extraction with phenol:chloroform. CSH Protoc. 2006; 2006 (1): pdb. prot 4455. doi: 10.1101/pdb.prot4455
15. Stenson P.D., Mort M., Ball E.V., Shaw K., Phillips A., Cooper D.N. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet. 2014; 133 (1): 1-9. doi: 10.1007/s00439-013-1358-4
16. Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., Voelkerding K., Rehm H.L., On behalf of the ACMG Laboratory Quality Assurance Committee. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17 (5): 405–424. doi: 10.1038/gim.2015.30
17. Marjamaa A., Salomaa V., Newton-Cheh C., Porthan K., Reunanen A., Karanko H., Jula A., Lahermo P., Väänänen H., Toivonen L., Swan H., Viitasalo M., Nieminen M.S., Peltonen L., Oikarinen L., Palotie A., Kontula K. High prevalence of four long QT syndrome founder mutations in the Finnish population. Ann Med. 2009; 41 (3): 234-240. doi: 10.1080/07853890802668530
18. Fodstad H., Bendahhou S., Rougier J. S., Laitinen-Forsblom P.J., Barhanin J., Abriel H., Schild L., Kontula K., Swan H. Molecular characterization of two founder mutations causing long QT syndrome and identification of compound heterozygous patients. Ann Med. 2006; 38 (4): 294-304. doi: 10.1080/07853890600756065
19. Koponen M., Havulinna A.S., Marjamaa A., Tuiskula A.M., Salomaa V., Laitinen-Forsblom P.J., Piippo K., Toivonen L., Kontula K., Viitasalo M., Swan H. Clinical and molecular genetic risk determinants in adult long QT syndrome type 1 and 2 patients: Koponen et al. Follow-up of adult LQTS patients. BMC Med Genet. 2018; 19 (1): 56. doi: 10.1186/s12881-018-0574-0
20. Maltese P.E., Orlova N., Krasikova E., Emelyanchik E., Cheremisina A., Kuscaeva A., Salmina A., Miotto R., Bonizzato A., Guerri G., Zuntini M., Nicoulina S., Bertelli M. Gene-Targeted Analysis of Clinically Diagnosed Long QT Russian Families. Int Heart J. 2017; 58 (1): 81-87. doi: 10.1536/ihj.16-133
21. Chanavat V., Janin A., Millat G. A fast and cost-effective molecular diagnostic tool for genetic diseases involved in sudden cardiac death. Clin Chim Acta. 2016; 453: 80-85. doi: 10.1016/j.cca.2015.12.011